Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 18/20 | 0.73 |
| ▸ | ARG2 | P78540 | 18/20 | 0.73 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL895418 | 0.99 | ARG1 (0.72) | ARG1ARG2MCHR1KCNH2 | |
| SCHEMBL20683458 | 0.85 | ARG1 (0.53) | ARG1ARG2MCHR1KCNH2 | |
| SCHEMBL895526 | 0.85 | ARG1 (0.72) | ARG1ARG2 | |
| SCHEMBL895504 | 0.85 | ARG1 (1.00) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894581 | 0.84 | ARG1 (0.70) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894097 | 0.84 | ARG1 (0.98) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL20485924 | 0.80 | ARG1 (0.49) | ARG1ARG2MCHR1KCNH2 | |
| SCHEMBL19575883 | 0.80 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL895916 | 0.80 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL30772139 | 0.80 | ARG1 (1.00) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190343852-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343852-A1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | ARG1, ARG2, PRMT3 | ARG1 1/4885ARG2 2/4885MCHR1 3901/4885 |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885MCHR1 894/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885MCHR1 894/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885MCHR1 894/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885MCHR1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.